InvestorsHub Logo
Followers 3
Posts 478
Boards Moderated 0
Alias Born 10/30/2016

Re: None

Wednesday, 09/12/2018 9:09:23 AM

Wednesday, September 12, 2018 9:09:23 AM

Post# of 48316
Here is the reason why I am going to hold all my ONCS shares for a long time.

PD-1 inhibitor market is exploring and projected to reach ~$30B by 2022. Keytruda sales alone is expected to hit over 5B in 2018, compares 3+B sales in 2017. Per Merck's 2Q2018 report, 2Q keytruda sales was 1.67B compared with 1.46B 1Q 2018 sales.

Keytruda sales is on a strong run due to its expanded 5 FDA approvals and it's became ~15% of Merck's total sales and the number may even jump higher with estimated keytruda sales to reach ~10B.

Merck has taken notice, as the ability to increase the efficacy of its PD-1 inhibitor keytruda would mean a huge competitive advantage and cement its head start in the immuno-oncology space. With that, what would be the ONCS's chances to be called from Merck or other big pharma companies?